(18)F-FDG Muscular Uptake in Statin-Associated Symptoms Without Myositis: How Long to Stop Treatment for Image Quality Improvement?

Statin-associated muscle symptoms are a frequent adverse effect of statin treatment and can lead to a statin-associated myopathy characterized by a significant serum creatine kinase increase. We report the case of an 80-year-old man who presented an increased muscular (18)F-FDG uptake in a statin-as...

Descripción completa

Detalles Bibliográficos
Autores principales: Metrard, Gilles, Besse, Helene, Callaud, Aurelien, Thibault, Frederique, Bailly, Matthieu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2022
Materias:
Interesting Images
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9653103/
https://www.ncbi.nlm.nih.gov/pubmed/36127793
http://dx.doi.org/10.1097/RLU.0000000000004389
_version_ 1784828612866736128
author Metrard, Gilles
Besse, Helene
Callaud, Aurelien
Thibault, Frederique
Bailly, Matthieu
author_facet Metrard, Gilles
Besse, Helene
Callaud, Aurelien
Thibault, Frederique
Bailly, Matthieu
author_sort Metrard, Gilles
collection PubMed
description Statin-associated muscle symptoms are a frequent adverse effect of statin treatment and can lead to a statin-associated myopathy characterized by a significant serum creatine kinase increase. We report the case of an 80-year-old man who presented an increased muscular (18)F-FDG uptake in a statin-associated muscle symptom without creatine kinase abnormality or inflammation. Statin treatment was discontinued for 6 hours, 3 days, and 7 days on consecutive follow-up examinations. The 1-week window clearly enhanced image quality. This case illustrates the possibility of diffuse muscular (18)F-FDG uptake without myositis and the need for a minimal 1-week statin discontinuation to reduce muscular uptake.
format Online
Article
Text
id pubmed-9653103
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Lippincott Williams & Wilkins
record_format MEDLINE/PubMed
spelling pubmed-96531032022-11-21 (18)F-FDG Muscular Uptake in Statin-Associated Symptoms Without Myositis: How Long to Stop Treatment for Image Quality Improvement? Metrard, Gilles Besse, Helene Callaud, Aurelien Thibault, Frederique Bailly, Matthieu Clin Nucl Med Interesting Images Statin-associated muscle symptoms are a frequent adverse effect of statin treatment and can lead to a statin-associated myopathy characterized by a significant serum creatine kinase increase. We report the case of an 80-year-old man who presented an increased muscular (18)F-FDG uptake in a statin-associated muscle symptom without creatine kinase abnormality or inflammation. Statin treatment was discontinued for 6 hours, 3 days, and 7 days on consecutive follow-up examinations. The 1-week window clearly enhanced image quality. This case illustrates the possibility of diffuse muscular (18)F-FDG uptake without myositis and the need for a minimal 1-week statin discontinuation to reduce muscular uptake. Lippincott Williams & Wilkins 2022-12 2022-09-21 /pmc/articles/PMC9653103/ /pubmed/36127793 http://dx.doi.org/10.1097/RLU.0000000000004389 Text en Copyright © 2022 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) , where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.
spellingShingle Interesting Images
Metrard, Gilles
Besse, Helene
Callaud, Aurelien
Thibault, Frederique
Bailly, Matthieu
(18)F-FDG Muscular Uptake in Statin-Associated Symptoms Without Myositis: How Long to Stop Treatment for Image Quality Improvement?
title (18)F-FDG Muscular Uptake in Statin-Associated Symptoms Without Myositis: How Long to Stop Treatment for Image Quality Improvement?
title_full (18)F-FDG Muscular Uptake in Statin-Associated Symptoms Without Myositis: How Long to Stop Treatment for Image Quality Improvement?
title_fullStr (18)F-FDG Muscular Uptake in Statin-Associated Symptoms Without Myositis: How Long to Stop Treatment for Image Quality Improvement?
title_full_unstemmed (18)F-FDG Muscular Uptake in Statin-Associated Symptoms Without Myositis: How Long to Stop Treatment for Image Quality Improvement?
title_short (18)F-FDG Muscular Uptake in Statin-Associated Symptoms Without Myositis: How Long to Stop Treatment for Image Quality Improvement?
title_sort (18)f-fdg muscular uptake in statin-associated symptoms without myositis: how long to stop treatment for image quality improvement?
topic Interesting Images
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9653103/
https://www.ncbi.nlm.nih.gov/pubmed/36127793
http://dx.doi.org/10.1097/RLU.0000000000004389
work_keys_str_mv AT metrardgilles 18ffdgmuscularuptakeinstatinassociatedsymptomswithoutmyositishowlongtostoptreatmentforimagequalityimprovement
AT bessehelene 18ffdgmuscularuptakeinstatinassociatedsymptomswithoutmyositishowlongtostoptreatmentforimagequalityimprovement
AT callaudaurelien 18ffdgmuscularuptakeinstatinassociatedsymptomswithoutmyositishowlongtostoptreatmentforimagequalityimprovement
AT thibaultfrederique 18ffdgmuscularuptakeinstatinassociatedsymptomswithoutmyositishowlongtostoptreatmentforimagequalityimprovement
AT baillymatthieu 18ffdgmuscularuptakeinstatinassociatedsymptomswithoutmyositishowlongtostoptreatmentforimagequalityimprovement

Ejemplares similares